CIK 0001048477
- Large accelerated filer
BIOMARIN PHARMACEUTICAL INC
Sign in to watch- Ticker
- BMRN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680397820
- Phone
- +1 415-506-6700
- Business address
- 105 DIGITAL DRIVE, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,466,459
- in 2 filings
Net −$1,466,459. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-07-17 | Acosta Andrea GVP, Chief Accouning Officer | Shares withheld for taxes | −285 | $128.21 | $37K | 14,674 |
| 2020-07-13 | FUCHS HENRY J President, Worldwide R&D | Exercise or conversion | +224 | $67.81 | $15K | 103,219 |
| 2020-07-13 | FUCHS HENRY J President, Worldwide R&D | Exercise or conversion | +13,810 | $67.81 | $936K | 117,029 |
| 2020-07-13 | FUCHS HENRY J President, Worldwide R&D | Exercise or conversion | +8,977 | $63.10 | $566K | 126,006 |
| 2020-07-13 | FUCHS HENRY J President, Worldwide R&D | Sale | −23,011 | $130.00 | $3.0M | 102,995 |
| 2020-07-13 | FUCHS HENRY J President, Worldwide R&D | Exercise or conversion · Stock Option (Right to buy Common Stock) | −224 | 1,250 | ||
| 2020-07-13 | FUCHS HENRY J President, Worldwide R&D | Exercise or conversion · Stock Option (Right to buy Common Stock) | −13,810 | 75,716 | ||
| 2020-07-13 | FUCHS HENRY J President, Worldwide R&D | Exercise or conversion · Stock Option (Right to buy Common Stock) | −8,977 | 49,423 | ||
| 2020-07-09 | BIENAIME JEAN JACQUES Chief Executive Officer | Gift | −425 | 247,533 | ||
| 2020-06-29 | Mueller Brian EVP, Chief Financial Officer | Grant or award | +4,640 | 29,744 | ||
| 2020-06-29 | Mueller Brian EVP, Chief Financial Officer | Grant or award · Stock Option (Right to buy Common Stock) | +13,230 | 13,230 | ||
| 2020-06-26 | Dere Willard H Director | Sale | −4,430 | $123.61 | $548K | 13,290 |
| 2020-06-19 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Exercise or conversion | +15,000 | $63.10 | $947K | 78,402 |
| 2020-06-19 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Sale | −15,000 | $124.00 | $1.9M | 63,402 |
| 2020-06-19 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Exercise or conversion · Stock Option (Right to buy Common Stock) | −15,000 | 15,700 | ||
| 2020-06-05 | LAWLIS V BRYAN Director | Sale | −4,430 | $107.46 | $476K | 18,850 |
| 2020-05-27 | Slamon Dennis Director | Grant or award | +4,300 | 22,915 | ||
| 2020-05-27 | PYOTT DAVID E I Director | Grant or award | +4,300 | 17,940 | ||
| 2020-05-27 | MEIER RICHARD A Director | Grant or award | +4,300 | 84,340 | ||
| 2020-05-27 | LAWLIS V BRYAN Director | Grant or award | +4,300 | 23,280 |
Page 35 of 36 · 707 trades